Thursday, July 19, 2012

Seeking Alpha: While Not Expensive, Both Halves Of Abbott Need Work

Drug, device, and nutrition conglomerate Abbott Labs (ABT) continues to oscillate just above and below the point where it looks like an interesting buy in the healthcare space. Valuation may not be too demanding, investors nevertheless have reason to pause before jumping into this name. On both sides of the soon-to-be-split business, there is real work that needs doing.

Read more here:
While Not Expensive, Both Halves Of Abbott Need Work

No comments: